TLDR
- B. Riley reduced Oklo’s price target to $92 from $129, sustaining its Buy recommendation
- Craig-Hallum decreased its target to $71 from $87, maintaining Hold, noting elevated capital requirements
- Needham slashed its target to $73 from $135, retaining Buy, suggesting approximately 20% potential gains
- Executives Jacob Dewitte (CEO) and Richard Bealmear (CFO) each offloaded approximately 72,000 shares at $60 per share on March 13; company insiders have divested roughly $170M in stock over the last 90 days
- Offsetting negative news, Oklo’s Atomic Alchemy division secured a DOE Nuclear Safety Design Agreement and NRC materials license
The nuclear energy startup Oklo has experienced a turbulent half-year period. Currently trading around $60.76, shares have plummeted 42% during this timeframe, sitting far beneath the 52-week peak of $193.84.
Multiple Wall Street firms adjusted their price expectations downward this week after the company released its Q4 2025 financial results. While targets were reduced, most analysts maintained their positive outlook — they’re simply resetting expectations.
B. Riley decreased its price objective from $129 to $92 while maintaining its Buy recommendation. The firm highlighted legitimate business achievements: Department of Energy approvals for the Aurora facility at Idaho National Laboratory, a prepayment contract with Meta for up to 1.2 gigawatts in Ohio, initial fuel facility development, and regulatory achievements for its Atomic Alchemy isotope division.
Needham similarly retained its Buy stance but dramatically reduced its target from $135 to $73. The revised price objective still suggests approximately 20% appreciation potential from current trading levels, and Wall Street’s consensus target hovers around $94.80 with a “Moderate Buy” rating.
Craig-Hallum adopted a more conservative position. The firm maintained its Hold rating while trimming its target from $87 to $71. Analysts revised their projections to reflect elevated operating expenses, increased capital expenditures, and adjusted timeline assumptions regarding future financing requirements. The firm also excluded anticipated 2026 isotope revenue — estimated below $5 million — from its financial model until greater visibility emerges.
Capital Needs and Insider Selling Weigh on Sentiment
Oklo closed Q4 2025 with $1.4 billion in available cash. Following quarter-end, the company secured an additional $1.2 billion in financing. For 2026, management projected operating cash consumption between $80 million and $100 million, combined with investing cash usage of $350 million to $450 million.
Despite the substantial cash position, the company recorded a trailing twelve-month EBITDA loss of $97 million and a full-year 2025 operating deficit of $139.3 million. Wall Street analysts don’t anticipate profitability in the current year.
Compounding investor concerns, CEO Jacob Dewitte divested approximately 72,960 shares on March 13 at $60 per share, representing roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares on the identical date at the same price point, valued at approximately $4.33 million. During the past 90 days, company insiders have collectively sold approximately 2.07 million shares totaling around $170 million. Despite these sales, insiders retain 18.9% ownership of the company.
Regulatory Progress Continues
Not all developments trend negatively. Oklo’s Atomic Alchemy subsidiary obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. The division also secured an NRC materials and isotope license — marking the first NRC license Oklo has obtained through an acquired subsidiary.
The company’s Aurora reactor earned its initial design approval from the Department of Energy, a critical milestone necessary to advance a 1.2-gigawatt power supply agreement with Meta, scheduled for delivery by 2034.
William Blair confirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight designation with a $122 price target. Barclays holds an Overweight rating with an $82 objective. Bank of America maintains a Buy rating with a $127 target.
Oklo’s 50-day moving average sits at $75.08 while its 200-day moving average rests at $95.27. The company maintains a market capitalization of approximately $9.49 billion.
